Familial Mediterranean Fever
Conditions
Brief summary
Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). It is due to mutations of the MEFV gene, encoding variants of the Pyrin inflammasome. Inflammasomes are protein complexes of innate immunity producing pro-inflammatory cytokines (interleukin-1β). In vitro, preliminary results demonstrated that activation of the Pyrin inflammasome (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in FMF patients compared to subjects with a similar clinical picture, and healthy controls. In addition, a measure of cell death yielded significant results in differentiating patients from controls. The investigators hypothesize that this fast and simple functional test can serve as a diagnostic tool for FMF.
Interventions
OTHERIn vitro functional test
Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Clinical picture compatible with an Familial Mediterranean Fever and an earlier genetic analysis finding a mutation of the MEFV gene; * Newly diagnosed or undergoing follow-up (without criteria of delay or evolutionary stage); * In the course of specific or non-specific treatment of the disease or without treatment; * For whom a blood test is planned as part of the routine care; * Of whom the informed non-opposition has been collected (parental authorization in the case of a minor patient);
Exclusion criteria
* patient under legal protection or under safeguard of justice or any other measures of protection (guardianship, curatorship); * Person unable to express his consent; * Person in emergency situation, vital or not; * Infection known to HIV and / or HBV and / or HCV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differences in interleukin-1bβ levels | Less than 48 hours | Quantification of the capacity of interleukin-1β concentration measured in primary monocyte supernatants in response to kinase inhibitors, to discriminate Familial Mediterranean Fever subjects from control subjects (healthy subjects and subjects with symptoms similar to those of Familial Mediterranean Fever). Analysis have to be performed Less than 48 hours after blood sampling (only one sampling). |
Countries
France
Outcome results
None listed